X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in Phase 3 clinical trials for the treatment of platinum resistant/refractory ovarian cancer.
Lead Product(s): Olvimulogene Nanivacirepvec
Therapeutic Area: Oncology Product Name: Olvi-Vec
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Genelux will use the net proceeds for advancement of clinical programs, including the Phase 3 registrational trial of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, non-pathogenic oncolytic vaccinia virus, in patients with platinum-resistant/refractory ovarian cancer.
Lead Product(s): Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: Olvi-Vec
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Benchmark Company
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 12, 2023
Details:
The proceeds will advance clinical programs, including Phase 3 of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, modified strain of the VACV, a stable DNA virus with a large engineering capacity, in patients with platinum resistant/refractory ovarian cancer.
Lead Product(s): Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Olvi-Vec
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Benchmark Company
Deal Size: $33.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 15, 2023
Details:
Olvimulogene Nanivacirepvec (olvi-vec) is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and therapeutic potential.
Lead Product(s): Olvimulogene Nanivacirepvec,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Olvi-Vec
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GOG Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
ELIAS Animal Health plans clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. Under the terms of the agreement, Genelux will receive an upfront payment, development and milestones, and royalties on product sales.
Lead Product(s): V-VET1
Therapeutic Area: Oncology Product Name: V-VET1
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ELIAS Animal Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 18, 2021
Details:
The Company intends to use the proceeds from the financing primarily to finalize preparations for and initiate its planned Phase 3 trial of Olvi-Vec in platinum refractory/resistant ovarian cancer.
Lead Product(s): Olvimulogene nanivacirepvec,Bevacizumab
Therapeutic Area: Oncology Product Name: Olvi-Vec
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Woodward Diversified Capital
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 25, 2020
Details:
Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows promising overall survival benefit in this heavily pretreated late-stage patient population.
Lead Product(s): Olvimulogene nanivacirepvec,Bevacizumab
Therapeutic Area: Oncology Product Name: Olvi-Vec
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
